Industry Insight
Discovery Technology
Analytical Laboratory Technology
Biopharma
Manufacturing
Delivery Systems
Ingredients, Formulation and Finishing
Bioprocessing
View our other publications with free access to extensive archives
  To print this article:
Existing subscribers please log in:
 
  USER NAME  
  PASSWORD  
   Or select

Or become a subscriber
 
 
 

Jesús Zurdo, Rebecca Michael and Yvette Stallwood at Lonza Biologics, and Karin Hedman and Teodor Aastrup at Attana AB of Biopharmaceuticals

The combination of computational and protein engineering tools with novel orthogonal methods of measuring aggregation can be used to assess the developability of biopharm products in the early stages of development, thereby reducing the level of risk in later stages.

Jesús Zurdo, Rebecca Michael and Yvette Stallwood at Lonza Biologics, and Karin Hedman and Teodor Aastrup at Attana AB (June 2011)

    View full article    |    Back to Manufacturing section




Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPTonline © 2004 The Pharmaceutical Technology Journal | Terms and Conditions | info@iptonline.com | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |